Is Harvard Bioscience Inc halal to invest in?

According to Musaffa's Shariah screening methodology, Harvard Bioscience Inc (HBIO) is currently classified as NOT HALAL as of March 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Harvard Bioscience Inc a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Harvard Bioscience Inc using these criteria to determine its compliance status.

Can Muslims buy shares of Harvard Bioscience Inc?

Muslim investors may consider investing in Harvard Bioscience Inc if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Harvard Bioscience Inc classified as NOT HALAL?

Musaffa determines the Shariah status of Harvard Bioscience Inc by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Harvard Bioscience Inc updated?

The Shariah compliance status of Harvard Bioscience Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Harvard Bioscience Inc become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Harvard Bioscience Inc?

You can check the latest Shariah compliance status of Harvard Bioscience Inc on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

HBIO Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: March 16, 2026

Report Source: 2025 Annual Report

Analyst's Ratings for Harvard Bioscience Inc (HBIO)

Based on 8 analysts giving stock ratings to Harvard Bioscience Inc in the past 3 months

Strong
SellSellHoldBuyStrong
Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Harvard Bioscience Inc. Stock Analysis HBIO

United States Health Care Nano Cap Report: 2025 Annual

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. The company is headquartered in Holliston, Massachusetts and currently employs 316 full-time employees. The company went IPO on 2013-10-21. The Company’s products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to pharmaceutical, biotechnology and contract research organizations (CROs). Its two product categories are cellular and molecular technology (CMT) and Preclinical. Its CMT product family includes the Harvard Apparatus, Biochrom, BTX, HEKA, KD Scientific, MCS and Warner brands. Its Preclinical product family provides a complete platform to assess physiological data from organisms for research ranging from basic research to drug discovery, and drug development services. The Preclinical Product family includes the DSI, Panlab, Hugo Sachs and Buxco brands.

Key Statistics of Harvard Bioscience Inc (HBIO)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$5.25$5.48

Today's Open

$5.44

Volume

26.45K

P/E Ratio (TTM)

52 Week Range

$2.81$9.46

Market Cap

29.65M

Avg. Volume

42.58K

Dividend Yield

Financial Metrics & Statements of Harvard Bioscience Inc (HBIO)

FAQ's for Harvard Bioscience Inc (HBIO)

According to Musaffa’s Shariah screening methodology, Harvard Bioscience Inc (HBIO) is currently classified as NOT HALAL as of March 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.